Home

Publications

40SCORE publications after 33 months from the start of the project.

Peer Reviewed and Published Scientific Publications

  1. Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds  Linlin Zhang, McClane Howland, Rolf Hilgenfeld, Marc O Anderson, Scott Eagon. Bioorg Med Chem Lett 2021 Jun 1;41:127990 doi: https://doi.org/10.1016/j.bmcl.2021.127990
  2. A molecular pore spans the double membrane of the coronavirus replication organelle  Georg Wolff, Ronald W.A.L. Limpens, Jessika C. Zevenhoven-Dobbe, Ulrike Laugks, Shawn Zheng, Anja W. M. de Jong, Roman I. Koning, David A. Agard, Kay Grünewald, Abraham J. Koster, Eric J. Snijder, Montserrat Bárcena Science 2020 Sep 11;369(6509):1395-1398 doi: https://doi.org/10.1126/science.abd3629
  3. Drugs against SARS-CoV-2: What do we know about their mode of action? Coralie Valle, Baptiste Martin, Franck Touret, Ashleigh Shannon, Bruno Canard, Jean-Claude Guillemot, Bruno Coutard, Etienne Decroly. Rev Med Virol. 2020 Aug 11 : e2143  doi: https://doi.org/10.1002/rmv.2143
  4. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. Abdelnabi R, Boudewijns R, Foo CS, Seldeslachts L, Sanchez-Felipe L, Zhang X, Delang L, Maes P, Kaptein SJF, Weynand B, Vande Velde G, Neyts J, Dallmeier K. EBioMedicine. 2021 Jun; 68:103403. doi:10.1016/j.ebiom.2021.103403. 
  5. A Fluorescence-based High Throughput-Screening assay for the SARS-CoV RNA synthesis complex. Cecilia Eydoux, Veronique Fattorini, Ashleigh Shannon, Thi-Tuyet-Nhung Le, Bruno Didier, Bruno Canard, Jean-Claude Guillemot. J Virol Methods 2021 Feb;288:114013.; doi: https://doi.org/10.1016/j.jviromet.2020.114013 
  6. A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate. Lorena Sanchez Felipe, Thomas Vercruysse, Sapna Sharma, Ji Ma1, Viktor Lemmens Dominique van Looveren, Mahadesh Prasad Arkalagud Javarappa, Robbert Boudewijns, Bert alengier-Devlies, Suzanne F. Kaptein, Laurens Liesenborghs, Carolien De Keyzer, Lindsey Bervoets, Madina Rasulova, Laura Seldeslachts, Sander Jansen, Michael Bright Yakass, Osbourne Quaye, Li-Hsin Li, Xin Zhang, Sebastiaan ter Horst, Niraj Mishra, Lotte Coelmont, Christopher Cawthorne, Koen Van Laere, Ghislain Opdenakker, Greetje Van de Veld, Birgit Weynand, Dirk E. Teuwen, Patrick Matthys,  Johan Neyts.  Nature 590, 320–325 (2021). doi: https://doi.org/10.1038/s41586-020-3035-9 
  7. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.  Ashleigh Shannon, Barbara Selisko, Nhung-Thi-Tuyet Le, Johanna Huchting, Franck Touret, Géraldine Piorkowski, Véronique Fattorini, François Ferron, Etienne Decroly, Chris Meier, Bruno Coutard, Olve Peersen & Bruno Canard. Nat Comm. 2020 Sep 17;11(1):4682. doi: https://doi.org/10.1038/s41467-020-18463-z 
  8. SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
    Wioletta Rut, Katarzyna Groborz, Linlin Zhang, Xinyuanyuan Sun, Mikolaj Zmudzinski, Bartlomiej Pawlik, Xinyu Wang, Dirk Jochmans, Johan Neyts, Wojciech Młynarski, Rolf Hilgenfeld & Marcin Drag. Nature Chemical Biology volume 17, pages222–228 (2021 October. doi: https://doi.org/10.1038/s41589-020-00689-z 
  9. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity. Suzanne JF Kaptein, Sofie Jacobs, Lana Langendries, Laura Seldeslachts, Sebastiaan ter Horst, Laurens Liesenborghs, Bart Hens, Valentijn Vergote, Elisabeth Heylen, Elke Maas, Carolien De Keyzer, Lindsey Bervoets, Jasper Rymenants, Tina Van Buyten, Hendrik Jan Thibaut, Kai Dallmeier, Robbert Boudewijns, Jens Wouters, Patrick Augustijns, Nick Verougstraete, Christopher Cawthorne, Birgit Weynand, Pieter Annaert, Isabel Spriet, Greetje Vande Velde, Johan Neyts, Joana Rocha-Pereira, Leen Delang. PNAS October 27, 2020 117 (43) 26955-26965; doi: https://doi.org/10.1073/pnas.2014441117 
  10. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamster. Robbert Boudewijns, Hendrik Jan Thibaut, Suzanne J. F. Kaptein, Rong Li, Valentijn Vergote, Laura Seldeslachts, Carolien De Keyzer, Lindsey Bervoets, Sapna Sharma, Johan Van Weyenbergh, Laurens Liesenborghs, Ji Ma, Sander Jansen, Dominique Van Looveren, Thomas Vercruysse, Dirk Jochmans, Xinyu Wang, Erik Martens, Kenny Roose, Dorien De Vlieger, Bert Schepens, Tina Van Buyten, Sofie Jacobs, Yanan Liu, Joan Martí-Carreras, Bert Vanmechelen, Tony Wawina-Bokalanga, Leen Delang, Joana Rocha-Pereira, Lotte Coelmont, Winston Chiu, Pieter Leyssen, Elisabeth Heylen, Dominique Schols, Lanjiao Wang, Lila Close, Jelle Matthijnssens, Marc Van Ranst, Veerle Compernolle, Georg Schramm, Koen Van Laere, Xavier Saelens, Nico Callewaert, Ghislain Opdenakker, Piet Maes, Birgit Weynand, Christopher Cawthorne, Greetje Vande Velde, Zhongde Wang, Johan Neyts, Kai Dallmeier. Nat Comm 11, 5838, 2020; doi: https://doi.org/10.1038/s41467-020-19684-y 
  11. The nucleotide addition cycle of the SARS-CoV-2 polymerase. Subhas Chandra Bera, Mona Seifert, Robert N. Kirchdoerfer, Pauline van Nies, Yibulayin Wubulikasimu, Salina Quack, Flávia S. Papini, Jamie J. Arnold, Bruno Canard, Craig E. Cameron, Martin Depken, David Dulin. Cell Reports. Vol36, Issue 9, 31 Aug 2021, 109650; doi: https://doi.org/10.1016/j.celrep.2021.109650 
  12. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs: a single molecule perspective. Mona Seifert, Subhas Chandra Bera, Pauline van Nies, Robert N. Kirchdoerfer, Ashleigh Shannon, Thi-Tuyet-Nhung Le, Xiangzhi Meng, Hongjie Xia, James M. Wood, Lawrence D. Harris, Flávia S. Papini, Jamie J. Arnold, Steven C. Almo, Tyler L. Grove, Pei-Yong Shi, Yan Xiang, Bruno Canard, Martin Depken, Craig E. Cameron, David Dulin. eLife, 10. ISSN 2050-084X; doi: https://doi.org/10.7554/elife.70968 
  13. In Vitro Activity of Itraconazole Against SARS-CoV-2. Ellen Van Damme, Sandra De Meyer, Denisa Bojkova, Sandra Ciesek, Jindrich Cinatl, Steven De Jonghe, Dirk Jochmans, Pieter Leyssen, Christophe Buyck, Johan Neyts, Marnix Van Loock. J Med Virol. 2021 Jul;93(7):4454-4460; doi: https://doi.org/10.1002/jmv.26917
  14. The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein, Xin Zhang, Lana Langendries, Laura Vangeel, Judith Breuer, Juanita Pang, Rachel Williams, Valentijn Vergote, Elisabeth Heylen, Pieter Leyssen, Kai Dallmeier, Lotte Coelmont, Dirk Jochmans, Arnab K. Chatterjee, Steven De Jonghe, Birgit Weynand, Johan Neyts. Lancet vol.27, Oct. 2021, 103595 ; doi: https://doi.org/10.1016/j.ebiom.2021.103595 
  15. The enzymatic activity of the nsp14 exoribonuclease Is critical for replication of MERS-CoV and SARS-CoV-2. Ogando NS, Zevenhoven-Dobbe JC, van der Meer Y, Bredenbeek PJ, Posthuma CC, Snijder EJ. J Virol. (2020) 94(23):e01246-20. doi: https://doi.org/10.1128/JVI.01246-20 
  16. Structure-function analysis of the nsp14 N7-guanine methyltransferase reveals an essential role in betacoronavirus replication. Natacha S. Ogando, Priscila El Kazzi, Jessika C. Zevenhoven-Dobbe, Brenda W. Bontes,  Alice Decombe, Clara C. Posthuma, Volker Thiel, Bruno Canard, François Ferron, Etienne Decroly, Eric J. Snijder. PNAS December 7, 2021 118 (49) e2108709118.  doi: https://doi.org/10.1073/pnas.2108709118 
  17. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. Rana Abdelnabi, Caroline S Foo, Steven De Jonghe, Piet Maes, Birgit Weynand, Johan Neyts. The Journal of Infectious Diseases, Volume 224, Issue 5, 1 September 2021, Pages 749–753, doi: https://doi.org/10.1093/infdis/jiab361
  18. COVID-19 and the intensive care unit: vaccines to the rescue. Kai Dallmeier, Geert Meyfroidt, Johan Neyts. Intensive Care Medicine volume 47, pages 786–789 (2021). doi: https://doi.org/10.1007/s00134-021-06414-1 
  19. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. Andrea Torneri, Pieter Libin, Joris Vanderlocht, Anne-Mieke Vandamme, Johan Neyts and Niel Hens.BMC Med 18, 191 (2020. doi:  https://doi.org/10.1186/s12916-020-01636-4 
  20. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. Laurens Liesenborghs, Isabel Spriet, Pharm.D Dirk Jochmans, Ann Belmans, Iwein Gyselinck, Laure-Anne Teuwen, Sebastiaan ter Horst, Erwin Dreesen, Tatjana Geukens, Matthias M. Engelen, Ewout Landeloos, Vincent Geldhof, Helga Ceunen, Barbara Debaveye, Bert Vandenberk, Lorenz Van der Linden, Sofie Jacobs, Lana Langendries, Robbert Boudewijns, Thuc Nguyen Dan Do, Winston Chiu, Xinyu Wang. Xin Zhang. Birgit Weynand, Thomas Vanassche, Timothy Devos, Geert Meyfroidt, Wim Janssens, Robin Vos, Pieter Vermeersch, Joost Wauters, Geert Verbeke, Paul De Munter, M.D. Suzanne J.F. Kaptein, Joana Rocha-Pereira, Leen Delang, Eric Van Wijngaerden, Johan Neyts, and Peter Verhamme. EBioMedicine. 2021 Apr; 66: 103288. doi: https://doi.org/10.1016/j.ebiom.2021.103288 
  21. Medical treatment options for COVID-19.Leen Delang and Johan Neyts. Eur Heart J Acute Cardiovasc Care. 2020 Apr 1; 9(3):209-214.doi: https://doi.org/10.1177/2048872620922790 
  22. Comparing infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters. Rana Abdelnabi, Robbert Boudewijns, Caroline S. Foo, Laura Seldeslachts, Lorena Sanchez-Felipe, Xin Zhang, Leen Delang, Piet Maes, Suzanne J. F. Kaptein, Birgit Weynand, Greetje Vande Velde, Johan Neyts, Kai Dallmeier. EBioMedicine. 2021 Jun;68:103403. doi: https://doi.org/10.1016/j.ebiom.2021.103403
  23. Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies. Mikolaj Zmudzinski, Wioletta Rut, Kamila Olech, Jarosław Granda, Mirosław Giurg, Małgorzata Burda-Grabowska, Linlin Zhang, Xinyuanyuan Sun, Zongyang Lv, Digant Nayak, Malgorzata Kesik-Brodacka, Shaun K. Olsen, Rolf Hilgenfeld, Marcin Drag. Biochem Biophys Res Commun. 2021 Jan 29; 538: 72–79. https://doi.org/10.1016/j.bbrc.2020.11.083   
  24. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Laura Vangeel, Steven De Jonghe, Piet Maes, Bram Slechten, Joren Raymenants, Emmanuel André,  Johan Neyts,  Dirk Jochmans. Antiviral Research 198, 2022, 105252 doi: https://doi.org/10.1101/2021.12.27.474275 
  25. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Rana Abdelnabi, Caroline S. Foo, Xin Zhang, Viktor Lemmens, Piet Maes, Bram Slechten, Joren Raymenants, Emmanuel André, Birgit Weynand, Kai Dallemier, Johan Neyts. Antiviral Res. 2022 Jan 21;198:105253. https://doi.org/10.1016/j.antiviral.2022.105253
  26. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Ashleigh Shannon, Véronique Fattorini, Bhawna Sama, Barbara Selisko, Mikael Feracci, Camille Falcou, Pierre Gauffre, Priscila El Kazzi, Adrien Delpal, Etienne Decroly, Karine Alvarez, Cécilia Eydoux, Jean-Claude Guillemot, Adel Moussa, Steven S. Good, Paolo La Colla, Kai Lin, Jean-Pierre Sommadossi, Yingxiao Zhu, Xiaodong Yan, Hui Shi, François Ferron & Bruno Canard. Nat Commun 13, 621 (2022). https://doi.org/10.1038/s41467-022-28113-1
  27. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-1 2 variants of concern. Rana Abdelnabi, Caroline S. Foo, Dirk Jochmans, Laura Vangeel, Steven De Jonghe, Patrick Augustijns, Raf Mols, Birgit Weynand, Thanaporn Wattanakul, Richard M. Hoglund, Joel Tarning, Charles E. Mowbray, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain, Johan Neyts. Nat Commun 13, 719 (2022). doi: https://doi.org/10.1038/s41467-022-28354-0 
  28. Synthesis, Structure–Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication. Dorothée Bardiot, Laura Vangeel, Mohamed Koukni, Philippe Arzel, Marleen Zwaagstra, Heyrhyoung Lyoo, Patrick Wanningen, Shamshad Ahmad, Linlin Zhang, Xinyuanyuan Sun, Adrien Delpal, Cecilia Eydoux, Jean-Claude Guillemot, Eveline Lescrinier, Hugo Klaassen, Pieter Leyssen, Dirk Jochmans, Karolien Castermans, Rolf Hilgenfeld, Colin Robinson, Etienne Decroly, Bruno Canard, Eric J Snijder, Martijn J van Hemert, Frank van Kuppeveld, Patrick Chaltin, Johan Neyts, Steven De Jonghe, Arnaud Marchand. Molecules. 2022 Feb 4;27(3):1052. https://doi.org/10.3390/molecules27031052   
  29. Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model. Caroline S. Foo ,Rana Abdelnabi ,Laura Vangeel ,Steven De Jonghe, Dirk Jochmans, Birgit Weynand and Johan Neyts. Microorganisms 2022, 10(3), 633; https://doi.org/10.3390/microorganisms10030633     
  30. From repurposing to redesign: Optimization of boceprevir to highly potent inhibitors of the SARS-CoV-2 main protease.  Matthias Göhl1, Linlin Zhang, Haifa El Kilani, Xinyuanyuan Sun, Kaixuan Zhang, Mark Brönstrup, Rolf Hilgenfeld. Molecules 2022, 27(13), 4292; https://doi.org/10.3390/molecules27134292     
  31. Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures. Winston Chiu, Lore Verschueren, Christel Van den Eynde, Christophe Buyck, Sandra De Meyer, Dirk Jochmans, Denisa Bojkova, Sandra Ciesek, Jindrich Cinatl, Steven De Jonghe, Pieter Leyssen, Johan Neyts, Marnix Van Loock, Ellen Van Damme.  J Med Virol. 2022 Jul;94(7):3101-3111. https://doi.org/10.1002/jmv.27683      
  32. Biodistribution and Environmental Safety of a Live-attenuated YF17D-vectored SARS-CoV-2 Vaccine Candidate. Li-Hsin Li, Laurens Liesenborghs, Lanjiao Wang, Marleen Lox, Michael Bright Yakass, Sander Jansen, Ana Lucia Rosales Rosas, Xin Zhang, Hendrik Jan Thibaut, Dirk Teuwen, Johan Neyts, Leen Delang, Kai Dallmeier Molecular Therapy - Methods & Clinical Development https://doi.org/10.1016/j.omtm.2022.03.010
  33. A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection. Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein, Robbert Boudewijns, Laura Vangeel, Steven De Jonghe, Dirk Jochamns, Birgit Weynand, Johan Neyts. J Virol. 2022 Aug 24;96(16):e0075822. https://doi.org/10.1128/jvi.00758-22
  34. Diastereomeric resolution yields highly potent inhibitor of SARS-CoV-2 main protease. Mark S. Cooper, Linlin Zhang, Kaixuan Zhang, Xinyuanyuan Sun, Judith Röske, Matthias Göhl, Mark Brönstrup, Lucie Sauerhering, Stephan Becker, Laura Vangeel, Dirk Jochmans, Johan Neyts, Katharina Rox, Graham P. Marsh, Hannah J. Maple,  Rolf Hilgenfeld. J. Med. Chem. 2022, 65, 19, 13328–1334 Doi: https://doi.org/10.1021/acs.jmedchem.2c01131
  35. Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay. Hernández S, Feracci M, De Jesus CT, El Kazzi P, Kaci R, Garlatti L, Mondielli C, Bailly F, Cotelle P, Touret F, de Lamballerie X, Coutard B, Decroly E, Canard B, Ferron F, Alvarez K. Antiviral Res. 2022 Aug;204:105364. doi: 10.1016/j.antiviral.2022.105364.
  36. The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 1 phenotype 2. G.Tuba Barut, Nico Joel Halwe, Adriano Taddeo, Jenna N. Kelly, Jacob Schön, Nadine Ebert, Lorenz Ulrich, Christelle Devisme, Silvio Steiner, Bettina Salome Trüeb, Bernd Hoffmann, Inês Berenguer Veiga, Nathan Georges François Leborgne, Etori Aguiar Moreira, Angele Breithaupt, Claudia Wylezich, Dirk Höper Kerstin Wernike, Aurélie Godel, Lisa Thomann, Vera Flück, Hanspeter Stalder Melanie Brügger, Blandina I. Oliveira Esteves, Beatrice Zumkehr, Guillaume Beilleau, Annika Kratzel, Kimberly Schmied, Sarah Ochsenbein, Reto M. Lang, Manon Wider, Carlos Machahua, Patrick Dorn, Thomas M. Marti, Manuela Funke-Chambour, Andri Rauch, Marek Widera, Sandra Ciesek, Ronald Dijkman, Donata  Hoffmann, Marco P. Alves, Charaf Benarafa1, Martin Beer,Volker Thiel. Barut et al. 2022 Nature Communications 13:5929 https://doi.org/10.1038/s41467-022-33632-y  

Submitted SCORE publications which have not yet been published.

  1. A high-throughput fluorescence polarization assay to discover inhibitors of arenavirus and coronavirus exoribonucleases  Sergio Hernández,  Mikael Feracci, Carolina Trajano De Jesus, Priscila El-Kazzi, Rafik Kaci, Laura Garlatti, Etienne Decroly,  Bruno Canard,  François Ferron,  Karine Alvarez.  bioRxiV doi: https://doi.org/10.1101/2021.04.02.437736
  2. Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging. Rut W., Groborz K., Zhang L., Sun X.,  Zmudzinskia M., Pawlik B., Wang X., Jochmans D., Neyts J., Młynarski W., Hilgenfeld R., Drag M. doi: https://doi.org/10.1101/2020.03.07.981928 
  3. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. A. Shannon, B. Selisko, NTT Le, J. Huchting, F. Touret, G. Piorkowski, V. Fattorini, F. Ferron, E. Decroly, C Meier, B. Coutard, O. Peersen, B. Canard. bioRxiv 2020.05.15.098731; doi: https://doi.org/10.1101/2020.05.15.098731 
  4. Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron). Maya Imbrechts, Winnie Kerstens, Madina Rasulova, Thomas Vercruysse, Wim Maes, Louanne Ampofo, Karen Ven, Jeroen Lammertyn, Karen Vanhoorelbeke, Nico Callewaert, Johan Neyts, Kai Dallmeier, Paul Declerck, Hendrik Jan Thibaut, Nick Geukens. bioRxiv 2021.12.21.473706; doi: https://doi.org/10.1101/2021.12.21.473706